Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis

Psoriasis Clinical Trial

Official title:

Rôle du métabolisme du Glucose Dans la Migration Des Cellules Dendritiques cutanées Dans le Psoriasis : étude Pilote Translationnelle

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05399433
• Other study ID #: 21-PP-25
• Status: Recruiting
• Phase: N/A
• Start date: June 30, 2022
• Est. completion date: September 1, 2026

Study information

• Verified date: September 2023
• Source: Centre Hospitalier Universitaire de Nice
• Contact: PASSERON Thierry, PhD
• Phone: +33492036488
• Email: passeron.t[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dendritic cells (DC) paly a key role in the induction and chronicity of psoriasis by capturing the antigenes and activating the T cell repsonse. This activation requires their migration from the cutaneous sensitisation site to the lymph nodes. This migration requires an important intracellular metabolic activity, with a strong involvmenet of glucdic metabolism. This activity is linked with the systemic activity. This study aims to compare the migration and the phenotypic and metabolic caracteristics of blood and skin DCs in patients with or without psoriasis and with or without type 2 diabetes,

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 1, 2026
• Est. primary completion date: June 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients of both sexes

• hospitalized in the Dermatology department of the CHU of Nice for moderate to severe psoriasis (defined by a PASI > or = 10)

• covered by a social security scheme after obtaining a free

• Clinical diagnosis of plaque psoriasis by a dermatologist with or without type 2 diabetes (defined by glycated hemoglobin >7%)

• For the control group: without psoriasis or other inflammatory dermatosis aged in the presence or not of type 2 diabetes (glycated hemoglobin >7%).

• free and informed consent

Exclusion Criteria:

• Minor or incapable or unwilling to consent freely or in an informed manner Pregnant or nursing woman.

• Patient in a period of exclusion from other biomedical research

• Patient with generalized chronic inflammatory disease or other inflammatory dermatosis

• Patients on general corticosteroid, immunomodulator or immunosuppressant therapy in the month prior to local inclusion or treatment with corticosteroid therapy in the 15 days prior to inclusion, on anti- treatmentIL-23 or anti IL12/23 for less than 3 months or under anti-IL-17 or anti-TNF treatment for less than 1 month.

• Contraindication to cutaneous biospsis (known hemostasis disorder, taking anticoagulants, allergy to xylocaine, history of cheloid scars, congenital immune deficiency)

Related Conditions & MeSH terms

• Psoriasis

Intervention

Other:
• Biopsy and venous blood
A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed. Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis

Locations

Country	Name	City	State
France	CHU de Nice	Nice	Alpes-maritimes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of dentridic cells producers of IL-23	Alterations in the percentage of dentridic cells that have migrated with the metabolic status of patients	at baseline
Secondary	Percentage of subpopulations dentridic cells producers	Study of the percentage of the various cDC subpopulations according to the metabolic status of the patients.	At baseline